Clinical Trials
MK-1084 + SQ Pembrolizumab + MK-3475A vs. MK3475A + Chemo in 1st Line KRAS G12C-Mutant NCSLC
Disease Type: Lung
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville